2871872-79-4
Chemical Structure
DS96432529
- CAS No.: 2871872-79-4
- Formula:C18H26N4O3S
- Molecular Weight:378.49
IUPAC Name: (S)-3-amino-4-(3-((2-ethoxyethoxy)methyl)piperidin-1-yl)thieno[2,3-b]pyridine-2-carboxamide
InChIKey: GOAKYBVMJUXOFY-LBPRGKRZSA-N
SMILES: O=C(C1=C(N)C2=C(N3C[C@@H](COCCOCC)CCC3)C=CN=C2S1)N
Biological Activity: DS96432529 is an orally active CDK8 inhibitor with an IC50 of 33 nM. DS96432529 enhances ALPase activity, with an EC200 of 63 nM. DS96432529 inhibits TNF-α-induced activation of the RLR signaling pathway, activates mitophagy, accelerates mineralized nodule formation, and suppresses the proliferation of periodontal ligament stem cells. DS96432529 promotes bone formation, alleviates ligation-induced alveolar bone loss, and increases bone mineral density in ovariectomized animal models. DS96432529 can be used in studies related to periodontitis and osteoporosis[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
DS96432529 | 99.93% | DS96432529 is an orally active CDK8 inhibitor with an IC50 of 33 nM. DS96432529 enhances ALPase activity, with an EC200 of 63 nM. DS96432529 inhibits TNF-α-induced activation of the RLR signaling pathway, activates mitophagy, accelerates mineralized nodule formation, and suppresses the proliferation of periodontal ligament stem cells. DS96432529 promotes bone formation, alleviates ligation-induced alveolar bone loss, and increases bone mineral density in ovariectomized animal models. DS96432529 can be used in studies related to periodontitis and osteoporosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DS96432529 (Standard) | 99.75% | DS96432529 (Standard) is the analytical standard of DS96432529 (HY-145121). This product is intended for research and analytical applications. DS96432529 is an orally active CDK8 inhibitor with an IC50 of 33 nM. DS96432529 enhances ALPase activity, with an EC200 of 63 nM. DS96432529 inhibits TNF-α-induced activation of the RLR signaling pathway, activates mitophagy, accelerates mineralized nodule formation, and suppresses the proliferation of periodontal ligament stem cells. DS96432529 promotes bone formation, alleviates ligation-induced alveolar bone loss, and increases bone mineral density in ovariectomized animal models. DS96432529 can be used in studies related to periodontitis and osteoporosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.49
HY-13019BI605906 -
Similarity Score 0.44
HY-W070753LIMK1 inhibitor 2 -
Similarity Score 0.44
HY-151515Dopamine D2 receptor agonist-2 -
Similarity Score 0.44
HY-116204SKLB70326 -
Similarity Score 0.43
HY-101841LY 2033298 -
Similarity Score 0.43
HY-182938Autophagy activator-2 -
Similarity Score 0.43
HY-16615SIRT-IN-1 -
Similarity Score 0.43
HY-13340VU0152100 -
Similarity Score 0.43
HY-147028M4 mAChR agonist-1 -
Explore the MedChemAI to find more analogs
References
- [1]. He H, et al. DS96432529 enhances osteogenic differentiation and mitigates inflammatory damage in periodontal ligament stem cells involving mitophagy-related processes. Stem cell research & therapy. 2026 Mar 20;17(1):159. [Content Brief]
-
[2]. Saito K, et al. Discovery of 3-amino-4-{(3S)-3-[(2-ethoxyethoxy)methyl]piperidin-1-yl}thieno[2,3-b]pyridine-2-carboxamide (DS96432529): A potent and orally active bone anabolic agent. Bioorg Med Chem Lett. 2021 Dec 15;54:128440.
[Content Brief]
